Loading…
← CockpitCompetitor Analysis › OCS Oculis Holding AGOpen in the cockpit ↗

Oculis Holding AGOCSCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services
Momentum laggard 8
Mkt cap
$456M
US dollars, full cap
Free float
76%
of shares outstanding
$/day
$2.34M
20-day average traded
P/B
1.83×
price to book
ROE
-48.9%
delivered
Implied ROE
9.5%
what the price asks
Next earnings
124 days
22 Mar 2027
Close · USD$7.39
1D-1.6%
1W-2.9%
1M-1.3%
3M-43.8%
6M-73.5%
YTD-63.0%
1Y-61.4%
ATR %7.9%
Beta1.05
52w lowhigh78.6% off high

What Oculis does

Employees: 60

Oculis at a glance

Size Oculis (OCS) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $456M, the 2743rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.39 on 18 Nov 2026.

Performance Over six months the shares fell 73.5%, against +1.8% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 8 in its peer set.

Valuation It trades at 1.83× book value against a peer median of 2.24× (4th cheapest of 8).

Price implies The share price implies a return on equity of about 9.5%; Oculis delivers -48.9%, so the price asks more than the business earns today.

Short interest Short interest is 2.6% of the free float (30 Oct 2026).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026Peer median 102OCS 24
Six months, rebased to 100: Oculis against the median of its 7 peers (local-currency closes).

Oculis financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$755,357-$657,446-$461,014-$319,367-$313,068
EBITDA-$113M-$99.1M-$83.4M-$51.7M-$34.5M
Net income-$101M-$119M-$97.4M-$98.8M-$40.5M
Free cash flow-$87.2M-$78.8M-$54.2M-$60.0M-$26.3M
Capital expenditure$70,654$1.67M$261,166$53,413$3.71M
Total debt$3.34M$2.92M$1.30M$718,826$133M

Quarterly statements and history in the cockpit →

Oculis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%-10%0%+10%EVHTECXEVTANLSBCOABISLNOCS6-month return →1-month return →
Up and to the right = strong over both horizons. Oculis is the large dot.

Fundamentals: return on equity against price-to-book

-75%-50%-25%0%25%20×40×60×EVHTECXEVTANLSBCOABISLNOCSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Oculis is the large dot.

Capital: ROE delivered against the ROE the price implies

-50%0%50%-50%0%50%EVHTECXEVTANLSBCOABISLNOCSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Oculis is the large dot.

Oculis competitors and peer comparison

How Oculis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oculis against its 7 peers (data as of 18 Nov 2026)
MeasureOCSPeer medianRank in peer set
1-month return-1.3%+0.2%4th lowest of 8
6-month return-73.5%+1.8%lowest of 8
Return on equity-48.9%-25.1%2nd lowest of 8
Price / book1.83×2.24×4th cheapest of 8
ROE the price implies9.5%16.5%2nd least demanding of 8
ROE delivered-48.9%-25.1%2nd lowest of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Oculis OCSUnited States$456M-74%n/a-49%1.83×9.5%-48.9%
Evolent Health EVHUnited States$445M+2%+14%-84%1.19×11.6%-83.6%
Tectonic Therapeutic TECXUnited States$420M-27%n/a-35%1.57×16.5%-35.5%
Evotec EVT.DEGermany$532M-46%-5%-25%0.76×8.8%-25.1%
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-20%2.62×27.5%-20.3%
SBC Medical SBCUnited States$645M+94%+7%19%2.24×13.4%19.4%
OmniAb OABIUnited States$741M+97%+91%-17%2.97×18.0%-16.5%
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-36%5.73×53.1%-35.6%

Questions

Which companies are Oculis's closest peers?
The cockpit's peer set: Evolent Health (EVH), Tectonic Therapeutic (TECX), Evotec (EVT.DE), Adlai Nortye Ltd. Sponsored ADR (ANL), SBC Medical (SBC), OmniAb (OABI), Silence Therapeutics PLC Sponsored ADR (SLN).
Is Oculis expensive compared with its peers?
On price / book it trades at 1.83× against a peer median of 2.24×, 4th cheapest of 8 in its peer set. The share price implies a return on equity of about 9.5%; Oculis delivers -48.9%, so the price asks more than the business earns today.
How has Oculis stock performed?
Over six months to 18 Nov 2026 the shares returned -73.5% against +1.8% for the median peer; over one year -61.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.